Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ NY-ESO-1-Specific T Cells and the NY-ESO-1 Immunostimulatory Agents LV305 or CMB305 For Patients With Sarcoma

Next Previous
Trial Profile

Phase I Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ NY-ESO-1-Specific T Cells and the NY-ESO-1 Immunostimulatory Agents LV305 or CMB305 For Patients With Sarcoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aldesleukin (Primary) ; CMB 305 (Primary) ; Cyclophosphamide (Primary) ; LV 305 (Primary) ; T lymphocyte cell therapies (Primary)
  • Indications Liposarcoma; Myxoid liposarcoma; Sarcoma; Synovial sarcoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 31 Aug 2023 Status changed from active, no longer recruiting to completed.
  • 25 Feb 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2022.
  • 03 May 2021 Number of treatment arms is decreased from 3 to 2, by removing experimental cohort 2 arm.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top